-- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA ...
This review is led by Professor Kongming Wu (State Key Laboratory for Biology of Plant Diseases and Insect Pests, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing, ...
The Costs They Are a-Rising: Commercialization Costs and the Innovation Process in Drug Development.
Commercialization is a crucial phase in the innovation process and its associated costs significantly influence R&D decisions. Yet our understanding of how commercialization costs impact various ...
Advances in precision oncology have transformed cancer treatment, offering life-saving therapies to patients with limited options. However, the development of personalized medicine introduces ...
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Oramed ...
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), today announced that it has entered into an exclusive worldwide license and collaboration agreement with Novartis ...
The PharmaJet Needle-free Delivery System has shown effective uptake of the SCIB1 DNA vaccine in addition to offering speed, convenience, and enhanced patient experience. PharmaJet is eligible to ...
SAINT LOUIS, Feb. 19, 2019 /PRNewswire/ -- Oakrum Pharma, LLC (Oakrum) announced today that it has entered into an agreement with Aucta Pharmaceuticals, Inc (Aucta) to develop and manufacture four ...
NEWARK, Del., March 30, 2023 /PRNewswire/ -- With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services ...
Leading through change is hard. According to McKinsey's research, only 31% of organizations do it successfully. But, change is necessary if a business wants to take its place in the market and make ...
New York, NY, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Healixa, Inc. (OTC: EMOR) ("Healixa," or the "Company"), a technology company focusing on building and acquiring innovative and disruptive technologies ...
The Costs They Are a-Rising: Commercialization Costs and the Innovation Process in Drug Development.
Khoshsokhan, Sina. The Costs They Are a-Rising: Commercialization Costs and the Innovation Process in Drug Development. Academy of Management Annual Meeting Proceedings. 2024, Vol. 2024 Issue 1, p1-6.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback